Industry News
Pharmaceutical Industry News
Just days after AbbVie unveiled a…
Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly.
Amid a viral social media trend…
Amid a viral social media trend glorifying the halcyon days of 2016, Novo Nordisk has gone back an extra decade to find inspiration for its latest direct-to-consumer Ozempic campaign.
With Fujifilm Biotechnologies now…
With Fujifilm Biotechnologies now among the top echelon of CDMOs by biologics capacity, Fujifilm’s group CEO reflected on the unit’s unique facility design philosophy and how it’s eschewing big M&A plays to expand in-house.
For the fourth year running—and…
For the fourth year running—and the third in a row for Skyrizi specifically—an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.
Exelixis may only have one drug on…
Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big.
Trump Outlines Health Care Proposals as Prices and Premiums Rise
The long-awaited plan would leave much to Congress and calls for payments to health savings accounts rather than insurance subsidies, among other broad proposals.
On this episode of “The Top Line,”…
On this episode of "The Top Line," we dig into how turmoil at the FDA impacted drug approvals in 2025.
New York’s attorney general has…
New York's attorney general has filed an insider trading lawsuit against former Emergent BioSolutions CEO Robert Kramer, accusing him of selling company shares and receiving more than $10 million before the company revealed contamination issues
The Truth About Weight-Loss Drugs Like Ozempic: You Probably Need Them Forever
Many people who use these medications don’t want to stay on them long term. But research has repeatedly shown that quitting the drugs means gaining back weight.
RTI Health Solutions experts…
RTI Health Solutions experts explain how HEOR and real-world evidence are reshaping access decisions—and why clear communication is essential.
Under CEO Richard Francis, Teva…
Under CEO Richard Francis, Teva has long been looking to reframe itself as an innovative drugmaker on par with industry peers. Now, Francis says the company is on track to complete its transformation into a
President Donald Trump has hinted…
President Donald Trump has hinted at "concepts of a plan" for healthcare for months as legislators debate the future of key subsidies under the Affordable Care Act, and on Thursday the White House unveiled a
The steady stream of FDA untitled…
The steady stream of FDA untitled letters that began in September is showing no signs of letting up in the new year.
The FDA has told the makers of six…
The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of the risk of febrile seizures which can occur after childhood
In this week’s Asia news recap,…
In this week's Asia news recap, AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space, while Illumina's CEO detailed the company's efforts to work with authorities in China. In addition, Astellas CEO
Becton, Dickinson and Company will…
Becton, Dickinson and Company will shell out $110 million to expand prefillable syringe production at its Columbus, Nebraska, manufacturing plant. The move comes in response to increasing delivery demands for GLP-1s, plus broader conversations about
Just a month after Johnson &…
Just a month after Johnson & Johnson reported a successful study pairing its blood cancer treatments Tecvayli and Darzalex, the company has revealed another trial win. This time, Tecvayli excelled as a solo agent, reducing
Hologic has drafted professional…
Hologic has drafted professional basketball player Erica Wheeler to raise awareness of cervical cancer screening, putting the guard at the center of a drive to frame testing as the “Ultimate Defense.”
With Xtandi set to lose U.S….
With Xtandi set to lose U.S. patent protection next year, Astellas’ CEO fielded questions this week about his company’s dealmaking strategy ahead of the loss. Despite continuing to hunt for external innovation, helmsman Naoki Okamura
Even in the era of the FDA’s…
Even in the era of the FDA's Commissioner's National Priority Voucher program, Jazz Pharmaceuticals is showing that traditional priority review vouchers can catch a pretty penny.